LYKALABS

Lyka Labs Share Price

₹143.00 -0.31 (-0.22%)

21 Nov, 2024 14:08

SIP TrendupStart SIP in LYKALABS

Start SIP

Performance

  • Low
  • ₹142
  • High
  • ₹145
  • 52 Week Low
  • ₹98
  • 52 Week High
  • ₹173
  • Open Price₹145
  • Previous Close₹143
  • Volume45,939

Investment Returns

  • Over 1 Month -2.4%
  • Over 3 Month + 11.22%
  • Over 6 Month + 22.43%
  • Over 1 Year + 10.51%
SIP Lightning

Smart Investing Starts Here Start SIP with Lyka Labs for Steady Growth!

Invest Now

Lyka Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 136.6
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 473
  • P/B Ratio
  • 6.9
  • Average True Range
  • 8.21
  • EPS
  • 0.89
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.26
  • RSI
  • 48.83
  • MFI
  • 80.11

Lyka Labs Financials

Lyka Labs Technicals

EMA & SMA

Current Price
₹143.00
-0.31 (-0.22%)
pointer
  • stock-down_img
  • Bullish Moving Average 6
  • stock-up_img
  • Bearish Moving Average 10
  • 20 Day
  • ₹144.42
  • 50 Day
  • ₹143.07
  • 100 Day
  • ₹137.68
  • 200 Day
  • ₹130.80

Resistance and Support

143.65 Pivot Speed
  • R3 151.19
  • R2 148.79
  • R1 146.05
  • S1 140.91
  • S2 138.51
  • S3 135.77

What's your outlook on Lyka Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lyka Labs has an operating revenue of Rs. 131.60 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of -1% needs improvement, ROE of -3% is poor and needs improvement. The company has a debt to equity of 63%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 13% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lyka Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-10-11 Others Inter-alia, to consider and approve filling of fresh application of scheme of amalgamation of Lyka Exports Limited (Companys subsidiary) with the Company.
2024-08-09 Quarterly Results
2024-05-21 Audited Results & Others To consider other business matters
2024-04-16 Others inter alia: to allot and issue 26,00,000 Equity Shares upon conversion of 26,00,000 Warrants to Ipca Laboratories Limited, part of a Promoter Group.

Lyka Labs F&O

Lyka Labs Shareholding Pattern

58.1%
0.01%
0.28%
0.15%
0%
32.06%
9.4%

About Lyka Labs

  • NSE Symbol
  • LYKALABS
  • BSE Symbol
  • 500259
  • Managing Director & CEO
  • Mr. Kunal Gandhi
  • ISIN
  • INE933A01014

Similar Stocks to Lyka Labs

Lyka Labs FAQs

Lyka Labs share price is ₹143 As on 21 November, 2024 | 13:54

The Market Cap of Lyka Labs is ₹473.2 Cr As on 21 November, 2024 | 13:54

The P/E ratio of Lyka Labs is 136.6 As on 21 November, 2024 | 13:54

The PB ratio of Lyka Labs is 6.9 As on 21 November, 2024 | 13:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23